Prospective Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 92
- Locations
- 1
- Primary Endpoint
- Assessment of change of the Length of stay in the emergency service
Study Overview
Brief Summary
The rapid and accurate detection of influenza virus in respiratory specimens is required for optimal management of patients with acute respiratory infections. Because of the variability of the symptoms and the numerous other causes of influenza-like illness, the diagnosis of influenza cannot be made on the basis of clinical criteria alone. Thus, rapid influenza diagnostic tests have been developed such as the Alere i Influenza A&B isothermal nucleic acid assay. Investigators prospectively evaluated the performance of the Alere i Influenza A&B assay in comparison with the routine Xpert Flu/RSV assay.
Detailed Description
Main objective / secondary:
It appears that so far the weight of the influenza disease, the limits of clinical diagnosis and validity of rapid diagnostic methods to emergencies are well studied and validated. However the potential organizational and economic benefit in emergency care services remains little known and rarely evaluated.
The significant improvement in diagnostic response time he has a real beneficial impact for the patient? For the organization of the emergency? Investigators propose to study the impact of the implementation of rapid diagnostic solution by molecular biology of influenza directly available in an adult emergency department, from a cohort of patients consulting in connection a flu-like illness. Investigators wish in particular to highlight the organizational and economic impact.
Methodology :
DESIGN:
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Respiratory Symptoms include cough, dyspnea and / or
- •General symptoms: headache, myalgia, asthenia, anorexia ... and / or
- •Acute fever above 38 ° C
- •Patient consent.
Exclusion Criteria
- •Major cognitive disorders
- •Patient under guardianship
- •Patient refusing to consent to research
- •Duplicate (patients who have had laboratory diagnosis of influenza in previous 7 days)
- •Patient not receiving social security
Outcomes
Primary Outcomes
Assessment of change of the Length of stay in the emergency service
Time Frame: Day 1
Will be assessed with patients of the firt group (phase 1) and the second one (With Flu Test)
Assessment of change of Hospitalization rates
Time Frame: Day 1
Will be assessed with patients of the firt group (phase 1) and the second one (With Flu Test)
Secondary Outcomes
- Assessments of change of antibiotic treatment Costs(Day1)